

**CLAIMS**

1. A pharmaceutical composition for the treatment of diseases related to gastric hyperacidity, wherein it contains a combination of one or more histamine H2-receptor antagonists and tenatoprazole.

5 2. The composition according to claim 1, wherein the histamine H2-receptor antagonist is selected from cimetidine, ranitidine, famotidine and nizatidine.

10 3. The composition according to either claim 1 or claim 2, wherein the weight ratio between tenatoprazole and the histamine H2-receptor antagonist is between 1:30 and 1:2.

4. The composition according to any of the preceding claims, wherein it contains between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H2-receptor antagonist.

15 5. The composition according to claim 1, wherein tenatoprazole is in the form of a potassium, magnesium, sodium or calcium salt.

20 6. The composition according to any of the preceding claims, wherein it is presented in a form for oral or parenteral administration.

7. The combined use of tenatoprazole and at least one histamine H2-receptor antagonist in the manufacture of a medicinal product intended for the treatment of diseases related to gastric hyperacidity.

25 8. Use according to claim 7, wherein the medicament is aimed at treating gastric and duodenal ulcers, and symptoms and lesions related to gastroesophageal reflux.